What is the level of liabilities of Beigene this year?
Beigene has a debt balance of 16.02 B USD this year.
Beigene Liabilities 2024
Beigene Liabilities
16.02 B USD
Ticker
6160.HK
ISIN
KYG1146Y1017
WKN
A144EN
In 2024, Beigene's total liabilities amounted to 16.02 B USD, a 15.3% difference from the 13.89 B USD total liabilities in the previous year.
Beigene Aktienanalyse
What does Beigene do?
Beigene Ltd is a Chinese biotech company that is active in cancer research. It was founded in 2010 by experienced biotech manager John Oyler. The company is now listed on NASDAQ and also has a presence in the United States. Beigene's business model is to develop and distribute innovative cancer treatments. The company utilizes its extensive expertise in molecular and cellular biology as well as clinical development. The goal is to develop therapies that specifically target tumor cells while sparing healthy tissue. This is intended to improve patient survival rates and quality of life. Beigene specializes in the development of cancer treatments, particularly immunotherapies and precision medicine. The latter utilizes targeted attacks against tumor cells at the molecular level to achieve the most focused and effective treatment possible. The company focuses primarily on rare tumor types for which there are currently few or no effective therapies. Beigene is divided into several divisions that focus on different treatment approaches. One important division is immunotherapies, which activate the patient's own immune system against the tumor. Beigene develops antibodies, for example, that recognize and attack specific tumor cells. CAR-T cell therapy is also part of the company's portfolio. In this approach, the patient's T cells are harvested, genetically modified, and multiplied in the laboratory. These T cells are then reintroduced into the patient's body, where they target the tumor specifically. Another division of Beigene is the so-called small molecule drugs. These are chemical compounds that are introduced into the body and specifically attack tumor cells. Beigene develops inhibitors, for example, that inhibit specific enzymes and thus suppress the growth of cancer cells. Beigene has been particularly successful with its drug Zanubrutinib, which is used to treat lymphomas. The drug has achieved excellent results in clinical trials and has already been approved in several countries. Overall, Beigene is an innovative and promising biotech company that specializes in the development of new cancer treatments. The company has a strong expertise in molecular biology and has already achieved promising successes. With its various divisions and products, Beigene covers a wide range of treatment approaches and is likely to play an important role in the fight against cancer in the future. Beigene ist eines der beliebtesten Unternehmen auf Eulerpool.com.Liabilities Details
Assessing Beigene's Liabilities
Beigene's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating Beigene's financial stability, operational efficiency, and long-term viability.
Year-to-Year Comparison
By comparing Beigene's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.
Impact on Investments
Beigene's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.
Interpreting Liability Fluctuations
Shifts in Beigene’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.
Frequently Asked Questions about Beigene stock
What were the liabilities of Beigene compared to the previous year?
The liabilities of Beigene have increased by 15.3% increased compared to the previous year.
What are the consequences of high debt for investors of Beigene?
High liabilities can pose a risk for investors of Beigene, as they can weaken the company's financial position and impair its ability to meet its obligations.
What consequences do low liabilities have for investors in Beigene?
Low liabilities mean that Beigene has a strong financial position and is able to meet its obligations without overburdening its finances.
How does an increase in liabilities of Beigene affect the company?
An increase in liabilities of Beigene can lead to the company having more obligations and potentially find it more difficult to meet its financial commitments.
How does a reduction in the liabilities of Beigene affect the company?
A decrease in the liabilities of Beigene can lead to the company having fewer obligations and a stronger financial position, which can make it easier for the company to fulfill its financial commitments.
What are some factors that influence the liabilities of Beigene?
Some factors that can influence the liabilities of Beigene include investments, acquisitions, operating costs, and sales development.
Why is the level of liabilities of Beigene so important for investors?
The liabilities of Beigene are important for investors as they serve as an indicator of the company's financial stability and provide investors with information on how the company meets its financial obligations.
What strategic measures can Beigene take to modify the liabilities?
To change its liabilities, Beigene can take measures such as cost savings, increasing revenue, selling assets, raising investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to choose the best strategic actions.
How much dividend does Beigene pay?
Over the past 12 months, Beigene paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Beigene is expected to pay a dividend of 0 USD.
What is the dividend yield of Beigene?
The current dividend yield of Beigene is .
When does Beigene pay dividends?
Beigene pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Beigene?
Beigene paid dividends every year for the past 0 years.
What is the dividend of Beigene?
For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.
In which sector is Beigene located?
Beigene is assigned to the 'Health' sector.
Wann musste ich die Aktien von Beigene kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Beigene from 9/15/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 9/15/2024.
When did Beigene pay the last dividend?
The last dividend was paid out on 9/15/2024.
What was the dividend of Beigene in the year 2023?
In the year 2023, Beigene distributed 0 USD as dividends.
In which currency does Beigene pay out the dividend?
The dividends of Beigene are distributed in USD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von Beigene
Our stock analysis for Beigene Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Beigene Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
